Concepedia
Statistics
Publications
15
Citations
4.8K
H-Index
Active since
2000
Affiliations
Eli Lilly (United States)(Current)
Asklepios Klinik St. Georg
Heidelberg University
University Hospital Heidelberg
Institut Gustave Roussy
Clet Niyikiza is an author at Eli Lilly (United States) specializing in pharmacology, chemotherapy, and oncology.
Publications per year
2000–2023
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations
Medicine, Oncology, Pharmacology +13
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
Alan B. Sandler, John Nemunaitis, Claude Denham et al. · Journal of Clinical Oncology · 2000 · 719 citations
Medicine, Oncology, Pharmacology +14
Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2023 · 253 citations
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
Clet Niyikiza, Sharyn D. Baker, David E. Seitz et al. · PubMed · 2002 · 247 citations
Pharmacy, Pharmacology, Pharmacotherapy +17
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity
Joseph G. Reynolds, Elena Geretti, Bart S. Hendriks et al. · Toxicology and Applied Pharmacology · 2012 · 120 citations
1–5 of 15